Bristol-Myers Squibb Rights
CELG.RT
27 hedge funds and large institutions have $299K invested in Bristol-Myers Squibb Rights in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 4 closing their positions.
21% more capital invested
Capital invested by funds: $248K → $299K (+$51.2K)
0.01% more ownership
Funds ownership: 0.02% → 0.02% (+0.01%)
4% less funds holding
Funds holding: 28 → 27 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCA
Transcend Capital Advisors
Madison,
New Jersey
|
+$50.8K |
| 2 |
RIM
Redpoint Investment Management
Sydney, NSW,
Australia
|
+$9.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.05K |
| 2 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$1K |
| 3 |
PIMG
Patriot Investment Management Group
Knoxville,
Tennessee
|
-$840 |
| 4 |
First Manhattan
New York
|
-$431 |
| 5 |
CRIG
Charter Research & Investment Group
Southport,
Connecticut
|
-$229 |
CELG.RT Hedge Fund Activity: Q3 2020 in Review
27 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q3 2020, worth a combined $299K — up 21% from $248K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CELG.RT and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 0 added.
The largest buyer was Transcend Capital Advisors, opening a new position worth an estimated $50.8K. The largest seller was UBS Group, cutting an estimated $2.05K.
- 27 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q3 2020, down from 28 in Q2 2020.
- Funds reported $299K of Bristol-Myers Squibb Rights stock for Q3 2020, up 21% quarter-over-quarter.
- 3 funds opened new Bristol-Myers Squibb Rights positions in Q3 2020 and 4 closed out, a net change of -1 holder.
- The largest Bristol-Myers Squibb Rights buyer in Q3 2020 was Transcend Capital Advisors, an estimated $50.8K added.
- The largest Bristol-Myers Squibb Rights seller in Q3 2020 was UBS Group, an estimated $2.05K sold.
Based on aggregated 13F filings for Q3 2020.